892579-09-8

Basic information

• Product Name: N-Cyclopropyl-4-nitrobenzylaMine
• Synonyms: N-Cyclopropyl-4-nitrobenzylaMine
• CAS NO: 892579-09-8
• Molecular Formula: C10H12N2O2
• Molecular Weight: 192.21448
• Mol File: 892579-09-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: N-Cyclopropyl-4-nitrobenzylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Cyclopropyl-4-nitrobenzylaMine(892579-09-8)
• EPA Substance Registry System: N-Cyclopropyl-4-nitrobenzylaMine(892579-09-8)

Safety Data

• Hazardous Substances Data: 892579-09-8(Hazardous Substances Data)

Usage

General Description

N-cyclopropyl-4-nitrobenzylamine is a chemical compound that belongs to the class of amines. It is characterized by a cyclopropyl group attached to a 4-nitrobenzyl group, with an amine functional group. N-cyclopropyl-4-nitrobenzylamine is commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceuticals and biologically active compounds. It is also employed as a reagent in chemical reactions and as a substrate in catalytic processes. The unique structural features of N-cyclopropyl-4-nitrobenzylamine make it a valuable and versatile chemical compound with a wide range of applications in various fields of chemistry and industry.

Upstream product

• 765-30-0 Cyclopropylamine 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Relevant articles and documents

Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia

A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure-activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.